Recent progress in adjuvant discovery for peptide-based subunit vaccines

Azmi, Fazren; Fuaad, Abdullah Al Hadi Ahmad; Skwarczynski, Mariusz; Tóth, István

doi:10.4161/hv.27332

Cited by 203 publications

(187 citation statements)

References 145 publications

(151 reference statements)

Supporting

Mentioning

187

Contrasting

Order By: Relevance

“…To overcome these issues, subunit vaccines composed of nonliving or split pathogens are being developed [2]. However these require adjuvants to increase antigen immunogenicity.…”

Section: Introductionmentioning

confidence: 99%

Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

et al. 2015

View full text Add to dashboard Cite

“…To overcome these issues, subunit vaccines composed of nonliving or split pathogens are being developed [2]. However these require adjuvants to increase antigen immunogenicity.…”

Section: Introductionmentioning

confidence: 99%

Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

et al. 2015

View full text Add to dashboard Cite

“…While promising experiments have been published that employ J8 peptide delivery vehicles (14,15) or adjuvanted J8 peptide (10,16), this research has yet to lead to a commercially viable GAS vaccine, so novel systems need to be explored. An effective construct should concentrate the peptide antigen, protect it from degradation, enhance its cellular uptake, and adjuvant its immunogenicity in order to induce a robust immune response (17,18).…”

Section: Introductionmentioning

confidence: 99%

Peptide Amphiphile Micelles Self-Adjuvant Group A Streptococcal Vaccination

Trent

Ulery

Black

et al. 2014

AAPS J

View full text Add to dashboard Cite

Abstract. Delivery system design and adjuvant development are crucially important areas of research for improving vaccines. Peptide amphiphile micelles are a class of biomaterials that have the unique potential to function as both vaccine delivery vehicles and self-adjuvants. In this study, peptide amphiphiles comprised of a group A streptococcus B cell antigen (J8) and a dialkyl hydrophobic moiety (diC 16 ) were synthesized and organized into self-assembled micelles, driven by hydrophobic interactions among the alkyl tails. J8-diC 16 formed cylindrical micelles with highly α-helical peptide presented on their surfaces. Both the micelle length and secondary structure were shown to be enhanced by annealing. When injected into mice, J8-diC 16 micelles induced a strong IgG1 antibody response that was comparable to soluble J8 peptide supplemented with two classical adjuvants. It was discovered that micelle adjuvanticity requires the antigen be a part of the micelle since separation of J8 and the micelle was insufficient to induce an immune response. Additionally, the diC 16 tail appears to be non-immunogenic since it does not stimulate a pathogen recognition receptor whose agonist (Pam 3 Cys) possesses a very similar chemical structure. The research presented in this paper demonstrates the promise peptide amphiphile micelles have in improving the field of vaccine engineering.

show abstract

“…Cancer vaccines consist of peptide or protein antigens present in tumour cells and adjuvants that stimulate APCs. Protein antigens are generally less prone to degradation and require a weaker stimulant to be immunogenic (Azmi et al 2014). A number of different peptide/protein and adjuvant combinations are currently explored in clinical trials for endocrine cancers.…”

Section: Vaccinesmentioning

confidence: 99%

The role of the tumour microenvironment in immunotherapy

Gasser

Lim

Cheung

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Recent success in immunomodulating strategies in lung cancer and melanoma has prompted much enthusiasm in their potential to treat other advanced solid malignancies. However, their applications have shown variable success and are even ineffective against some tumours. The efficiency of immunotherapies relies on an immunogenic tumour microenvironment. The current field of cancer immunology has focused on understanding the interaction of cancer and host immune cells to break the state of immune tolerance and explain how molecular patterns of cytokines and chemokines affect tumour progression. Here, we review our current knowledge of how inherent properties of tumours and their different tumour microenvironments affect therapeutic outcome. We also discuss insights into recent multimodal therapeutic approaches that target tumour immune evasion and suppression to restore anti-tumour immunity.

show abstract

Recent progress in adjuvant discovery for peptide-based subunit vaccines

Cited by 203 publications

References 145 publications

Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

Peptide Amphiphile Micelles Self-Adjuvant Group A Streptococcal Vaccination

The role of the tumour microenvironment in immunotherapy

Contact Info

Product

Resources

About